Jun 14, 2018 8:00 am EDT SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018
Jun 6, 2018 8:30 am EDT SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology
May 8, 2018 4:20 pm EDT SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
May 1, 2018 8:30 am EDT SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Apr 23, 2018 8:00 am EDT SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
Apr 10, 2018 7:30 am EDT SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
